SCHEMBL4882847

SCHEMBL4882847

O=C(Cc1ccccc1)Nc1c2c(nn1-c1ccc(Cl)cc1)CSC2

nearest known ligand 0.69

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 3/20 0.66
MAPT P10636 2/20 0.61
TP53 P04637 1/20 0.57
TSHR P16473 2/20 0.56
KMT2A Q03164 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4883373 0.90 MAPT (0.59) ENPP2MAPTTP53TSHRKMT2A
SCHEMBL4874779 0.90 ENPP2 (0.81) ENPP2MAPTTP53TSHRKMT2A
SCHEMBL4874955 0.89 ENPP2 (0.66) ENPP2MAPTTSHRKMT2A
SCHEMBL4872832 0.84 ENPP2 (0.58) ENPP2MAPT
SCHEMBL4880680 0.84 TSHR (0.57) ENPP2MAPTTSHR
SCHEMBL4880715 0.83 TSHR (0.56) ENPP2MAPTTSHR
SCHEMBL13235183 0.81 MAPT (0.58) ENPP2MAPTTP53KMT2A
SCHEMBL4875036 0.80 TP53 (0.59) ENPP2MAPTTP53TSHRKMT2A
SCHEMBL4871061 0.80 TSHR (0.58) ENPP2MAPTTSHR
SCHEMBL4884595 0.79 LMNA (0.71) ENPP2MAPTTP53TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080249154-A1 Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates ONO PHARMACEUTICAL CO., LTD. (JP) 2008-10-09 US disclosed
EP-1698335-A1 PREVENTIVE AND/OR THERAPEUTIC AGENT FOR DISEASE IN WHICH MITOCHONDRIAL BENZODIAZEPINE RECEPTOR PARTICIPATES ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249154-A1 Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates MTNR1A, GSR, NLN ENPP2 2226/4885MAPT 2701/4885TP53 2534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.